How to appeal a Healthfirst thyroid eye disease (ted) — tepezza (teprotumumab) and igf-1r therapy denial
ACA §2719 + ERISA §503 · 60-day window · 30-day decision
The framework that applies to your appeal
Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.
Healthfirst-specific note: Provider-sponsored not-for-profit; largest Medicaid MCO in NY State (~1.8M members). Owned by ~30 NY hospital systems. NY DFS oversight. NY State Fair Hearing is escalation path for Medicaid denials; commercial appeals go to DFS external appeal program.
What Healthfirst typically denies for thyroid eye disease (ted) — tepezza (teprotumumab) and igf-1r therapy
Across Healthfirst's commercial and Medicare books, denials cluster around a small number of patterns. For thyroid eye disease (ted) — tepezza (teprotumumab) and igf-1r therapy, expect:
- NY State Medicaid Managed Care carve-outs
- Behavioral health prior auth
- Dental/vision coordination
- Out-of-network non-emergency
Treatments most often denied in this category
These are the thyroid eye disease (ted) — tepezza (teprotumumab) and igf-1r therapy treatments most often flagged for prior auth, step therapy, or medical necessity review:
- Tepezza standard course
- Tepezza re-treatment
- Tepezza chronic-stable
- IV methylprednisolone
- Oral prednisone
- Orbital radiotherapy
How to submit the appeal to Healthfirst
- Read the denial letter — note the exact denial reason code and the appeal deadline (60 days from the date on the letter).
- Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Healthfirst cited in the denial.
- File the appeal through Healthfirst's portal (members: https://healthfirst.org ; providers: https://hfdocs.healthfirst.org). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
- If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In NY, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.
Frequently asked questions
How long do I have to appeal a Healthfirst thyroid eye disease (ted) — tepezza (teprotumumab) and igf-1r therapy denial?
Healthfirst allows 60 days from the date on the denial letter to file an internal appeal. Standard decisions come back within 30 days; expedited decisions for urgent care typically within 72 hours.
What's the fastest way to submit a Healthfirst appeal?
Members can submit through the Healthfirst member portal at https://healthfirst.org. Providers should use the provider portal at https://hfdocs.healthfirst.org. Faxed and mailed appeals are accepted but take longer.
What denials does Healthfirst most often issue for thyroid eye disease (ted) — tepezza (teprotumumab) and igf-1r therapy?
Across Healthfirst's book of business the common patterns include: NY State Medicaid Managed Care carve-outs; Behavioral health prior auth; Dental/vision coordination. For thyroid eye disease (ted) — tepezza (teprotumumab) and igf-1r therapy specifically, expect denials tied to the FDA-approved indication, step therapy through cheaper alternatives, and prior authorization documentation gaps.
What if Healthfirst denies the appeal too?
After an internal appeal denial you have the right to an external review by an independent reviewer (IRO) — request it within 4 months of the final internal denial.
Start your Thyroid eye disease (TED) — Tepezza (teprotumumab) and IGF-1R therapy appeal
Upload your Healthfirst denial letter — DenialHelp drafts a physician-ready appeal in five minutes, aligned to ACA §2719 + ERISA §503.
Get started →Contact: hello@denialhelp.com